Are presently available insulin analogues clinically beneficial?

被引：29

作者：

Berger, M

Heinemann, L

机构：

[1] Department of Metabolic Diseases and Nutrition,

[2] (WHO Collaborating Centre for Diabetes),undefined

[3] Heinrich Heine University,undefined

[4] Düsseldorf,undefined

[5] Germany,undefined

来源：

DIABETOLOGIA | 1997年 / 40卷 / Suppl 2期

关键词：

insulin analogues; intensified insulin therapy; HbA(1c); hypoglycaemia; quality of life; insulin-dependent diabetes mellitus;

D O I：

10.1007/s001250051416

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

A number of insulin analogues have been developed by genetic engineering in order to improve the possibilities of substituting prandial and basal insulin requirements in diabetic patients by subcutaneous injection. For some short acting insulin analogues, in particular for [Lys(B28),Pro(B29)]-human insulin, preclinical and clinical trials have been performed. Despite the favourable pharmacokinetic and pharmacodynamic characteristics of these short-acting insulin analogues resulting in an attenuation of prandial hyperglycaemia following subcutaneous injection in diabetic patents, up to now, actual clinical benefits have not become apparent when they were used in clinical trials.

引用

页码：S91 / S96

页数：6

共 45 条

[1]

ANDERSON J, 1996, DIABETES S, V45, pA59

[2]

ANDERSON JH, 1995, DIABETES, V44, pA228

[3]

ABSORPTION KINETICS AND BIOLOGIC EFFECTS OF SUBCUTANEOUSLY INJECTED INSULIN PREPARATIONS [J].